Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) demonstrates superior efficacy, compared with chemotherapy, for patients with EGFR-mutant advanced non–small cell lung cancer (NSCLC).1 However, approximately 20% to 30% of patients who receive such treatment exhibit de novo resistance to therapy with EGFR TKIs.2 A better understanding of the underlying mechanisms of this phenomenon is imperative to optimize clinical outcomes.
Hong S, Gao F, Fu S, et al. Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non–Small Cell Lung Cancer. JAMA Oncol. 2018;4(5):739–742. doi:10.1001/jamaoncol.2018.0049
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: